(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, ...

Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

The FDA has issued a long-awaited approval of Novavax's COVID-19 vaccine (Nuvaxovid), but with unusual restrictions. Novavax makes the nation's only traditional protein-based coronavirus vaccine -- ...

Shares of Novavax Inc. NVAX slipped 2.25% to $8.67 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.95% to ...

The FDA recently approved new COVID-19 vaccines for Americans, but due to certain restrictions, there has been mounting confusion on what they are, how much protection they’ll offer and whether ...

The Food and Drug Administration has approved Novavax's Nuvaxovid 2025-2026 formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novavax ( (NVAX)) has issued an ...

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...

GAITHERSBURG, Md., Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™ 2025-2026 Formula for the ...

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. A closeup of a vial of the ...

The threat of another influenza pandemic arising from bird-to-human and then human-to-human transmission drives continuing efforts to develop effective vaccines against avian influenza. In the latest ...